Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 19/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24012260 | 0.88 | KLKB1 (0.56) | KLKB1 | |
| SCHEMBL31456735 | 0.88 | KLKB1 (0.44) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL20584557 | 0.88 | KLKB1 (0.44) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL20446635 | 0.88 | KLKB1 (0.44) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL21726682 | 0.88 | KLKB1 (0.44) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL29581014 | 0.85 | KLKB1 (0.74) | KLKB1 | |
| SCHEMBL20584586 | 0.85 | KLKB1 (0.74) | KLKB1 | |
| SCHEMBL24570715 | 0.84 | KLKB1 (0.70) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL22654214 | 0.83 | KLKB1 (0.52) | KLKB1CYP1A2POLBCYP3A4CYP2C19 | |
| SCHEMBL20584351 | 0.80 | KLKB1 (0.58) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019022-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3355890-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11066360-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066360-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | KLKB1 1/4885CYP1A2 1483/4885POLB 4045/4885 |
| US-20200361867-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885CYP1A2 1483/4885POLB 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.